vaniprevir + peginterferon alfa-2a + ribavirin

**vaniprevir + peginterferon alfa-2a + ribavirin** is a combination regimen used in the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1.\n- **Vaniprevir** (MK-7009) is a **macrocyclic HCV nonstructural protein 3/4A protease inhibitor** that blocks viral replication by inhibiting the NS3/4A protease, a key enzyme required for viral polyprotein processing and replication[1].\n- **Peginterferon alfa-2a** is a **recombinant interferon** covalently attached to polyethylene glycol, which increases its half-life and improves pharmacokinetics. Peginterferon stimulates innate and adaptive immune responses, enhancing the clearance of HCV-infected hepatocytes[3].\n- **Ribavirin** is a nucleoside analogue antiviral that interferes with viral RNA synthesis and induces lethal mutagenesis, further reducing viral replication.\nCombination of these three agents produces synergistic antiviral effects and higher rapid virologic response (RVR) and sustained virologic response (SVR) rates compared to peginterferon alfa-2a with ribavirin alone, with predictable resistance profile and generally favorable safety[1][4].